ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Differential Clinical Outcomes in Kidney Transplant Recipients With De Novo C1q+ and C1q- Donor Specific Antibodies

M. Ajaimy,1 A. Colovai,2 S. Calp,1 J. Lindower,1 M. Melamed,3 E. Akalin.1

1Transplantation, Einstein/Montefiore Transplant Center, Bronx
2Tissue Typing Laboratory, Einstein/Montefiore Transplant Center, Bronx
3General Nephrology, Einstein/Montefiore Teaching Hospital, Bronx.

Meeting: 2015 American Transplant Congress

Abstract number: 372

Keywords: Antibodies, Sensitization

Session Information

Session Name: Concurrent Session: Kidney: Antibodies and Allograft Injury

Session Type: Concurrent Session

Date: Tuesday, May 5, 2015

Session Time: 2:15pm-3:45pm

 Presentation Time: 2:39pm-2:51pm

Location: Room 118-AB

Background: We investigated the prevalence and clinical significance of C1q binding versus non-C1q binding de novo DSA in kidney transplant recipients.

Methods: The study group included consecutive patients who received kidney transplantation at our center between May 2009 and December 2012, and had no pre-formed DSA. Serum anti-HLA antibodies were monitored after transplantation at 3, 12 months and yearly thereafter, and at the time of clinically indicated biopsies. To characterize DSA specificity and complement binding capacity, conventional and C1q Single Antigen Bead assays were used.

.Results: Out of 284 patients, 31 (11%) developed de novo DSA during a median follow-up of 29 months (17, 50). Of these, 23% had class I, 46% had class II, and 31% showed both class I and II DSA. DSA directed to donor HLA-DQ were most frequently observed (48% of the patients with DSA). C1q+ DSA were identified in 11 out of 31 patients (35%). Overall, mean fluorescence intensity (MFI) values of class I C1q+ DSA were significantly higher compared to those of C1q- DSA (6476±3016 vs. 2471±1546 p=0.01) but not for class II (7198±3496 vs. 4616±3952, p=0.13). Incidence of acute and chronic AMR was significantly higher in the C1q+DSA+ (45% and 36%) group compared to the C1q-DSA (5% and 5%) and DSA- groups (1% and 2%) (p < 0.001).

Variable No DSA(N=253) De Novo C1q+ DSA(N=11) De Novo C1q- DSA(N=20) P value
Mean age at transplant 53±12.5 45.7±14.1 48.1±11.1 0.02
Gender, % female 39 66 50 0.62
Race, % African American 32 63 50 0.03
Transplant type, % living donor 31 36 20 0.54
Previous Transplant,% 9 0 10 0.56
Mean class I PRA 21±31 37±41 47±36 <0.001
Mean class II PRA 22±32 60±35 64±31 <0.001
Mean serum creatinine, mg/dl 1.4±0.6 2.2±1.2 1.5±0.4 0.001
Acute cellular rejection,% 5 9 5 0.81
Acute AMR, % 1 45 5 <0.001
Chronic AMR,% 2 36 5 <0.001
Graft survival,% 94 73 95 0.01
Patient survival,% 98 100 95 0.66
Furthermore, graft survival was lower in the C1q+DSA group (73%) compared to the C1q-DSA (95%) and DSA- (94%) groups. Patients with C1q+ DSA had higher creatinine levels compared to C1q-DSA and DSA- groups.

Conclusions: The development of C1q+ DSA after renal transplantation is associated with acute and chronic AMR, and lower graft survival and allograft function.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Ajaimy M, Colovai A, Calp S, Lindower J, Melamed M, Akalin E. Differential Clinical Outcomes in Kidney Transplant Recipients With De Novo C1q+ and C1q- Donor Specific Antibodies [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/differential-clinical-outcomes-in-kidney-transplant-recipients-with-de-novo-c1q-and-c1q-donor-specific-antibodies/. Accessed June 3, 2025.

« Back to 2015 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences